Evidence map›Paper›PMID 32546765›Full record

ArticleScientific reports2020

Assessment of Luminal and Basal Phenotypes in Bladder Cancer.

Charles C Guo, Jolanta Bondaruk, Hui Yao, Ziqiao Wang, Li Zhang, Sangkyou Lee, June-Goo Lee, David Cogdell, Miao Zhang, Guoliang Yang and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 2 pooled it
21.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 2 syntheses or guidelines pooled it, 166 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 1 country.

Charles C Guo *Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jolanta Bondaruk *Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hui Yao *Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ziqiao WangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Li ZhangDepartment of Environmental Health, University of Cincinnati, Cincinnati, Ohio, USA.
Sangkyou LeeDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
June-Goo LeeDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David CogdellDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Miao ZhangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Guoliang YangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vipulkumar DadhaniaDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Woonyoung ChoiJohns Hopkins Greenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, MD, USA.
Peng WeiDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianjun GaoDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dan TheodorescuSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, Los Angeles, CA, USA.
Christopher LogothetisDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Colin DinneyDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Marek KimmelDepartment of Statistics, Rice University, Houston, TX, USA.
John N WeinsteinDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David J McConkeyJohns Hopkins Greenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, MD, USA.
Bogdan CzerniakDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. bczernia@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USJohns Hopkins University · USCedars-Sinai Medical Center · USRice University · USUniversity of Cincinnati · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting Ral GTPases in Bladder CancerP50CA091846 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DINNEY, COLIN P.N., MCCONKEY, DAVID J. · 2001 to 2018
$37.4M
Regulation and Targeting of CD24 in Bladder CancerR01CA075115 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI THEODORESCU, DAN · 2003 to 2024
$7.0M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA091846NCI NIH HHS R01 CA075115
6 · The paper itself

Abstract

Genomic profiling studies have demonstrated that bladder cancer can be divided into two molecular subtypes referred to as luminal and basal with distinct clinical behaviors and sensitivities to frontline chemotherapy. We analyzed the mRNA expressions of signature luminal and basal genes in bladder cancer tumor samples from publicly available and MD Anderson Cancer Center cohorts. We developed a quantitative classifier referred to as basal to luminal transition (BLT) score which identified the molecular subtypes of bladder cancer with 80-94% sensitivity and 83-93% specificity. In order to facilitate molecular subtyping of bladder cancer in primary care centers, we analyzed the protein expressions of signature luminal (GATA3) and basal (KRT5/6) markers by immunohistochemistry, which identified molecular subtypes in over 80% of the cases. In conclusion, we provide a tool for assessment of molecular subtypes of bladder cancer in routine clinical practice.

Indexed as

Biomarkers, TumorCarcinoma, Transitional CellDatabases, GeneticGATA3 Transcription FactorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryKeratin-5Keratin-6PhenotypePrognosisSensitivity and SpecificityUrinary Bladder NeoplasmsBiomarkers, TumorGATA3 protein, humanGATA3 Transcription FactorKeratin-5Keratin-6KRT5 protein, humanKRT6A protein, human

Identifiers

PMID32546765
PMCPMC7298008
OpenAlexW3035746651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.